Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P N Durrington

Showing results (31-40 of 189) with videos related to

Pageof 19
Sort By:
Current Opinion in Lipidology|September 18, 1998
Lipid-lowering drugs: who gets what?P N Durrington, R Illingworth
Postgraduate Medical Journal|August 1, 1989
Borderline hypercholesterolaemia: when to introduce drugsD Bhatnagar, P N Durrington
Heart (British Cardiac Society)|April 17, 2001
Methods for the prediction of coronary heart disease riskP N Durrington, H Prais
Annals of Clinical Biochemistry|September 1, 1991
Clinical value of apolipoprotein measurementD Bhatnagar, P N Durrington
British Journal of Pharmacology|July 4, 2003
Squalene synthase inhibitorsV C Menys, P N Durrington
Current Opinion in Lipidology|November 11, 1999
Dyslipidemia and atherosclerosis: how much more evidence do we need?D R Illingworth, P N Durrington
Atherosclerosis|June 1, 1995
HDL, its enzymes and its potential to influence lipid peroxidationM I Mackness, P N Durrington
Lancet (London, England)|September 30, 1995
Paraoxonase: another factor in NIDDM cardiovascular diseaseM I Mackness, P N Durrington
Postgraduate Medical Journal|January 1, 1989
Therapeutic aspects of hyperlipidaemia in diabetesP N Durrington, P H Winocour
Atherosclerosis|May 1, 1985
Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemiaP N Durrington, J P Miller
Pageof 19

Showing results (31-40 of 189) with videos related to

Sort By:
Pageof 19
Current Opinion in Lipidology|September 18, 1998
Lipid-lowering drugs: who gets what?P N Durrington, R Illingworth
Postgraduate Medical Journal|August 1, 1989
Borderline hypercholesterolaemia: when to introduce drugsD Bhatnagar, P N Durrington
Heart (British Cardiac Society)|April 17, 2001
Methods for the prediction of coronary heart disease riskP N Durrington, H Prais
Annals of Clinical Biochemistry|September 1, 1991
Clinical value of apolipoprotein measurementD Bhatnagar, P N Durrington
British Journal of Pharmacology|July 4, 2003
Squalene synthase inhibitorsV C Menys, P N Durrington
Current Opinion in Lipidology|November 11, 1999
Dyslipidemia and atherosclerosis: how much more evidence do we need?D R Illingworth, P N Durrington
Atherosclerosis|June 1, 1995
HDL, its enzymes and its potential to influence lipid peroxidationM I Mackness, P N Durrington
Lancet (London, England)|September 30, 1995
Paraoxonase: another factor in NIDDM cardiovascular diseaseM I Mackness, P N Durrington
Postgraduate Medical Journal|January 1, 1989
Therapeutic aspects of hyperlipidaemia in diabetesP N Durrington, P H Winocour
Atherosclerosis|May 1, 1985
Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemiaP N Durrington, J P Miller
Pageof 19